[go: up one dir, main page]

ES2073394T3 - Constructos de anticuerpos bifuncionales y su utilizacion para destruir selectivamente las poblaciones celulares. - Google Patents

Constructos de anticuerpos bifuncionales y su utilizacion para destruir selectivamente las poblaciones celulares.

Info

Publication number
ES2073394T3
ES2073394T3 ES88108793T ES88108793T ES2073394T3 ES 2073394 T3 ES2073394 T3 ES 2073394T3 ES 88108793 T ES88108793 T ES 88108793T ES 88108793 T ES88108793 T ES 88108793T ES 2073394 T3 ES2073394 T3 ES 2073394T3
Authority
ES
Spain
Prior art keywords
antibody constructs
antibody component
bifunctional antibody
cellular populations
selectively destroy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88108793T
Other languages
English (en)
Inventor
Stuart F Schlossman
Charles F Scott Jr
John M Lambert
Walter A Blattler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Application granted granted Critical
Publication of ES2073394T3 publication Critical patent/ES2073394T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

UN CONJUNTO DE ANTICUERPOS HETERODIMERO BIFUNCIONAL COMPRENDIENDO (A) UN COMPONENTE DE ANTICUERPO CELULAR ANTI-DIANA UNIDO A B) UN COMPONENTE DE ANTICUERPO ANTI-LINFOCITO DONDE EL COMPONENTE DE ANICUERPO ANTI-LINFOCITO ES ESPECIFICO PARA LINFOCITOS ACTIVADOS. UN CONJUGADO MOLECULAR DE UNION SUPERFICIAL CELULA/ANTICUERPO BIFINCIONAL Y UN COMPONENTE ANTICUERPO HIBRIDO BIFUNCIONAL COMPRENDIENDO LAS ETAPAS QUE SE DETALLAN AN LA INVENCION. SE DESCRIBE DETALLADAMENTE EL METODO DE SELECCION DESTRUCTIVA DE POBLACIONES DE CELULAS DIANA.
ES88108793T 1987-06-10 1988-06-01 Constructos de anticuerpos bifuncionales y su utilizacion para destruir selectivamente las poblaciones celulares. Expired - Lifetime ES2073394T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6020587A 1987-06-10 1987-06-10

Publications (1)

Publication Number Publication Date
ES2073394T3 true ES2073394T3 (es) 1995-08-16

Family

ID=22028021

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88108793T Expired - Lifetime ES2073394T3 (es) 1987-06-10 1988-06-01 Constructos de anticuerpos bifuncionales y su utilizacion para destruir selectivamente las poblaciones celulares.

Country Status (4)

Country Link
EP (1) EP0294703B1 (es)
AT (1) ATE122238T1 (es)
DE (1) DE3853740T2 (es)
ES (1) ES2073394T3 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869620A (en) * 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
EP0415929A1 (en) * 1988-01-15 1991-03-13 Centocor, Inc. Heteroligating antibodies and therapeutic uses thereof
US4925648A (en) * 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5173293A (en) * 1989-02-23 1992-12-22 Becton Dickinson And Company Anti-T-cell antibodies as adjuvants
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
FR2649119A1 (fr) * 1989-06-30 1991-01-04 Centre Nat Rech Scient Procede de pilotage de retrovirus en utilisant des complexes bifonctionnels
AU6290090A (en) * 1989-08-29 1991-04-08 University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
US6027725A (en) 1991-11-25 2000-02-22 Enzon, Inc. Multivalent antigen-binding proteins
WO1994012520A1 (en) * 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
UA40577C2 (uk) * 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
US5723125A (en) * 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
ES2590912T3 (es) 1997-12-08 2016-11-24 Merck Patent Gmbh Proteínas de fusión heterodiméricas útiles para inmunoterapia dirigida y estimulación general del sistema inmunitario
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
DE60025832T2 (de) 1999-08-09 2006-08-31 Emd Lexigen Research Center Corp., Billerica Mehrere zytokin-antikörper komplexen
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
CN1406249B (zh) 2000-02-11 2010-06-16 默克专利股份有限公司 增加基于抗体的融合蛋白的循环半衰期
PT1294401E (pt) 2000-06-29 2007-11-09 Merck Patent Gmbh Aumento das respostas imunológicas mediadas por proteínas de fusão anticorpo-citoquina por tratamento combinado com agentes que aumentam a captação de imunocitoquinas
RU2003129528A (ru) 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
CN100503639C (zh) 2001-05-03 2009-06-24 默克专利有限公司 重组肿瘤特异性抗体及其应用
EP2354791A1 (en) 2001-12-04 2011-08-10 Merck Patent GmbH Immunocytokines with modulated selectivity
EP1622645B1 (en) * 2002-04-23 2013-10-23 Roger Williams Hospital Compositions and methods for stem cell delivery
NZ540194A (en) 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
EP1558650A2 (en) 2002-11-08 2005-08-03 Ablynx N.V. Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders
PT1572748E (pt) 2002-12-17 2010-09-28 Merck Patent Gmbh Anticorpo humanizado (h14.18) do anticorpo 14.18 de rato que se liga ao gd2 e a sua fusão com a il-2
JP2006517789A (ja) 2003-01-10 2006-08-03 アブリンクス エン．ヴェー． 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
EP2251357A1 (en) 2003-11-07 2010-11-17 Ablynx N.V. Camelidae single domain antibodies VHH directed against epidermal growth factor receptor and uses therefor
BRPI0418286A (pt) 2003-12-30 2007-05-02 Merck Patent Gmbh proteìnas de fusão de il-7
KR20060124656A (ko) 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 개선된 약물동태를 가지는 Ｆｃ-에리스로포이에틴 융합단백질
WO2005070967A2 (en) 2004-01-22 2005-08-04 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
US7670595B2 (en) 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
CN101072793B (zh) 2004-12-09 2012-06-20 默克专利有限公司 具有降低的免疫原性的il-7变体
CN103254309B (zh) 2005-05-18 2017-09-26 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
PL2444424T3 (pl) 2005-05-20 2019-01-31 Ablynx N.V. Ulepszone Nanociała TM do leczenia zaburzeń, w których pośredniczy agregacja
DK2270050T3 (da) 2005-12-30 2013-08-12 Merck Patent Gmbh Anti-CD19-antistoffer med nedsat immunogenicitet
CN101351475B (zh) 2005-12-30 2013-05-15 默克专利有限公司 具有提高的稳定性的白细胞介素12p40变体
AU2010238858A1 (en) 2009-04-22 2011-12-08 Merck Patent Gmbh Antibody fusion proteins with modified FcRn binding sites
WO2011049449A1 (en) 2009-10-22 2011-04-28 University Of Twente Vhh for application in tissue repair, organ regeneration, organ replacement and tissue engineering
EP3998281A1 (en) 2016-02-05 2022-05-18 Orionis Biosciences BV Cd8 binding agents
CN109069573B (zh) 2016-03-07 2022-04-05 弗拉芒区生物技术研究所 结合cd20的单结构域抗体
CA3023881A1 (en) 2016-05-13 2017-11-16 Orionis Biosciences Nv Therapeutic targeting of non-cellular structures
IL268346B2 (en) 2017-02-06 2024-08-01 Orionis Biosciences BV Targeted chimeric proteins and uses thereof
WO2019148089A1 (en) 2018-01-26 2019-08-01 Orionis Biosciences Inc. Xcr1 binding agents and uses thereof
CN112074267B (zh) 2018-02-05 2024-06-28 奥里尼斯生物科学公司股份有限公司 成纤维细胞结合剂及其用途
JP7489407B2 (ja) 2019-05-21 2024-05-23 ノバルティス アーゲー Ｃｄ１９結合分子及びその使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) * 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8626412D0 (en) * 1986-11-05 1986-12-03 Clark M R Antibodies
US4882424A (en) * 1987-05-11 1989-11-21 Dana-Farber Cancer Institute, Inc. Activation antigen

Also Published As

Publication number Publication date
ATE122238T1 (de) 1995-05-15
JPS643128A (en) 1989-01-06
EP0294703B1 (en) 1995-05-10
DE3853740T2 (de) 1995-11-09
EP0294703A2 (en) 1988-12-14
EP0294703A3 (en) 1990-06-27
DE3853740D1 (de) 1995-06-14

Similar Documents

Publication Publication Date Title
ES2073394T3 (es) Constructos de anticuerpos bifuncionales y su utilizacion para destruir selectivamente las poblaciones celulares.
FI913927A0 (fi) Rekombinantantikropp specifik foer cd3.
ES2045216T3 (es) Inmunoensayo y derivados polimeros de igg para la compensacion de factores de perturbacion en el inmunoensayo.
DE3852054D1 (de) Monoklonale Antikörper gegen Glycolipid-Antigene und ihre Verwendung.
ES2153444T3 (es) Anticuerpos contra interleucina-4 mamifera, y peptidos utiles como antigenos en su produccion.
ES2035317T3 (es) Un metodo para la deteccion y el analisis de celulas hematopoyeticas en una muestra.
BG31497A3 (bg) Метод за получаване на 4-амино-5-алкил-сулфонил ортонизамиди
ATE112687T1 (de) Mutanten des hiv-1 hüllproteins mit fehlenden hypervariabelen domänen.
ES2097747T3 (es) Molecula de adhesion intercelular 2 y sus ligandos de union.
FI902143A7 (fi) HIV-peptidit, keinotekoiset HIV-antigeenit ja immunomäärityspakkaukset
BG32115A4 (bg) Метод за получаване на хидантоини
ES2124215T3 (es) Unos anticuerpos monoclonales al fiv y polipeptidos relacionados y su metodo de obtencion.
ES2090052T3 (es) Anticuerpos monoclonales (mak) contra antigenos asociados a tumores, su preparacion y uso.
BG35327A3 (bg) Метод за получаване на пиридоксинови производни
ES2110993T3 (es) Anticuerpos monoclonales especificos para la toxina b de clostridium difficile.
BG40963A3 (en) Method for preparing 1, 3- disubstituted 2- oxyindols
DE69631972D1 (de) Proliferationsinhibitor von endothellzellen und dessen verwendung
DE68912462D1 (de) Xanthenfarbstoffe.
ES2042461T1 (es) Producto y procedimiento para el te\ido oxidativo del cabello.
ATE361363T1 (de) Impfstoff, der peroxiredoxin enthält
DE69328779D1 (de) Benzodiazepin-derivate sowie deren konjugate mit proteinen und polypeptiden
ES2052913T3 (es) Ensayo inmunoquimico en cuanto al factor estimulante de colonias de granulocitos-macrofagos.
ES2130703T3 (es) Conjugados de benzodiazepinas y proteinas y su utilizacion para la determinacion inmunologica de benzodiazepinas.
ES2001013A6 (es) Un metodo para la preparacion de anticuerpos especificos de histamina
ATE130757T1 (de) Adhäsionsrezeptor für laminin und dessen verwendung.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 294703

Country of ref document: ES